Detalhe da pesquisa
1.
TCR-independent CD137 (4-1BB) signaling promotes CD8+-exhausted T cell proliferation and terminal differentiation.
Immunity
; 56(7): 1631-1648.e10, 2023 07 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-37392737
2.
Eomes-Dependent Loss of the Co-activating Receptor CD226 Restrains CD8+ T Cell Anti-tumor Functions and Limits the Efficacy of Cancer Immunotherapy.
Immunity
; 53(4): 824-839.e10, 2020 10 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-33053331
3.
The Road Less Taken: Less Appreciated Pathways for Manipulating CD8+ T Cell Exhaustion.
Front Immunol
; 13: 926714, 2022.
Artigo
em Inglês
| MEDLINE | ID: mdl-35874734
4.
Chemotherapy followed by anti-CD137 mAb immunotherapy improves disease control in a mouse myeloma model.
JCI Insight
; 52019 06 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-31194697